ClinicalTrials.gg
CompletedNCT00686777Updated Apr 7, 2017Results posted

Pegylated Interferon (PEG-IFN) Alfa-2b and Low Dose Ribavirin for the Treatment of Chronic Hepatitis C Patients With Genotype 1 High Viral Load and Low Body Weight (Study P05172)(COMPLETED)

A Phase 4 interventional study of Pegylated Interferon alfa-2b and Ribavirin in Hepatitis C, Chronic, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2017-04-07.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
75
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2b · Hepatitis C, Chronic.

Enrollment
23rd of 39
75 · median 99
Started
2008
with 2 others
Phase 4
10 of 40
none open now
Registered
21st of 40
by date
Lead sponsor
25 of 40
Merck Sharp & Dohme LLC

Among the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic, this one is the 23rd largest by enrollment of the 39 interventional ones that give a count, is one of 3 that started in 2008, is one of 10 in phase 4, and was the 21st registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About peginterferon alfa-2b

peginterferon alfa-2b: first FDA approval 2001 (PEGINTRON), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic as a file.
02

Study summary

The objective is to evaluate the efficacy and safety of the combination therapy with subcutaneous (SC) Pegylated Interferon (PEG-IFN) alfa-2b 1.5 ug/kg/week plus low-dose ribavirin administered for 48 weeks in participants with chronic hepatitis C virus (HCV) who are infected with HCV genotype 1 high viral load, and weigh 50 kg or less.

03

Conditions studied

  • Hepatitis C, Chronic

Keywords

  • hepatitis C
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with chronic .
  • Minimum 20 years of age
  • Willing to use adequate during the course of the study.
  • Participants who can be hospitalized for at least 14 days since treatment initiation.
  • Positive for HCV genotype 1 (genotype 1a and 1b) with high viral load (HCV-RNA >=100 kIU/mL).
  • Participants weighing over 40 kg to 50 kg.
  • Hematology results of:

    • levels >=12 g/dL
    • neutrophils >=1,500/mm\^3
    • >=100,000/mm\^3

Exclusion criteria

Exclusion Criteria:

  • Previous ribavirin therapy.
  • Previous interferon therapy within 90 days of registration.
  • Participants who received treatment with injectable products containing glycyrrhizin/cysteine/glycine (Stronger Neo-Minophagen C, etc.), Shosaikoto, or ursodeoxycholic acid within 30 days before the start of treatment
  • Participants who received treatment with an antiviral or anti-tumor drug or who received immunomodulating therapy (including and radiotherapy) within 90 days before the start of treatment [excluding local administration and topical drugs].
  • Participants who received other drugs within 180 days before the start of treatment.
  • Hepatitis Bs (HBs) antigen-positive
  • Antinuclear antibodies >=1:160
  • Fasting blood glucose >=110 mg/dL (however, participants with fasting blood glucose of 110 mg/dL to \<126 mg/dL can be registered if is \<6.5%)
  • Participants diagnosed with liver cirrhosis in most recent celioscopy or liver .
  • Participants with or who have a history of any of the following: liver failure; hepatic encephalopathy, esophageal varices, or ascites; depression or schizophrenia requiring treatment or suicidal attempt or ideation; epileptic seizures requiring drug treatment; disease (such as Hashimoto's disease, Crohn's disease, ulcerative colitis, chronic rheumatoid arthritis, idiopathic thrombocytopenic purpura, systemic erythematosus, autoimmune hemolytic anemia, and scleroderma); hepatic cancer
  • Participants with any of the following: liver disease such as autoimmune hepatitis, alcoholic liver disease, and drug-induced hepatic impairment; hemophilia; arrhythmia requiring treatment and participants with or who have a history of angina pectoris, cardiac failure, myocardial infarction, or life-threatening arrhythmia; hypertension (systolic BP of 160 mmHg or more and diastolic BP of 100 mmHg or more) not possible to control with drug therapy; chronic pulmonary disease; hemoglobinopathy (thalassemia, sickle cell anemia); malignant tumor or who have a history of malignant tumor within the past 5 years; thyroid function disorder not controlled by drug therapy.
  • Participants with organ transplants (excluding cornea and hair transplants).
  • Participants with a history of to interferon preparations, nucleoside analogs, or biological products such as vaccine.
  • Participants with a specific response to PEG-IFN alfa-2b in a prick test to be conducted just before the initiation of treatment.
  • Participants who are pregnant or nursing (in the case of male Participants : partner is pregnant)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    PEG-IFN + Ribavirin

    Pegylated Interferon alfa-2b was administered to participants at 1.5 μg/kg subcutaneously once weekly for 48 weeks. Ribavirin was administered orally every day after morning and evening meals for 48 weeks at 400 mg/day.

    Biological: Pegylated Interferon alfa-2b · Drug: Ribavirin

Interventions

  • Pegylated Interferon alfa-2b 1.5 ug/kg SC once weekly for 48 weeks

    Also known as: SCH 54031

  • Ribavirin 400 mg/day orally

    Also known as: SCH 18908

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Sustained Virologic Response (SVR) at 24 Weeks After the End of Treatment (EOT) or Discontinuation

    SVR was defined as a viral response which was sustained at 24 weeks after the end of treatment as measured by Hepatitis C Virus Ribonucleic Acid (HCV-RNA) negativity. HCV-RNA negativity was assessed by an reverse transcriptase polymerase chain reaction (RT-PCR) method, where a negative response was defined by a negative qualitative HCV-RNA result.

    Time frame: Measured at 24 weeks after the end of treatment (at the end of follow-up)

  2. Number of Participants Discontinuing Treatment

    Prespecified adverse event discontinuance criteria included neutrophil count \<500 /mm3, platelet count \<50,000/mm3, and hemoglobin \<8.5 g/dL.

    Time frame: From time of first treatment to Week 48

Secondary outcomes

  1. Percentage of Participants With HCV-RNA Negativity at 24 Weeks of Treatment and at EOT

    HCV-RNA negativity was assessed by an RT-PCR method, where a negative response was defined by a negative qualitative HCV-RNA result.

    Time frame: Measured at 24 weeks of treatment and at EOT (Treatment week 48)

07

Results

Posted Jan 18, 2012

Participant flow

Participant flow — Overall Study
MilestonePegylated Interferon Alfa-2b (PEG-IFN) + Ribavirin
Started75
Completed 24 weeks of treatment69
Completed 48 weeks of treatment65
Included in follow-up (all treated)75
Completed 24 weeks of follow-up70
Completed65
Not completed10
Withdrew: Adverse event2
Withdrew: Pregnancy1
Withdrew: Withdrawal by subject2
Withdrew: Discontinuance criteria (specified aes)4
Withdrew: No visit1

Outcome measures

PrimaryPercentage of Participants With Sustained Virologic Response (SVR) at 24 Weeks After the End of Treatment (EOT) or Discontinuation

SVR was defined as a viral response which was sustained at 24 weeks after the end of treatment as measured by Hepatitis C Virus Ribonucleic Acid (HCV-RNA) negativity. HCV-RNA negativity was assessed by an reverse transcriptase polymerase chain reaction (RT-PCR) method, where a negative response was defined by a negative qualitative HCV-RNA result.

Time frame:
Measured at 24 weeks after the end of treatment (at the end of follow-up)
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Virologic Response (SVR) at 24 Weeks After the End of Treatment (EOT) or Discontinuation
percentage of participantsPEG-IFN + Ribavirin
Percentage of Participants With Sustained Virologic Response (SVR) at 24 Weeks After the End of Treatment (EOT) or Discontinuation30.7
SecondaryPercentage of Participants With HCV-RNA Negativity at 24 Weeks of Treatment and at EOT

HCV-RNA negativity was assessed by an RT-PCR method, where a negative response was defined by a negative qualitative HCV-RNA result.

Time frame:
Measured at 24 weeks of treatment and at EOT (Treatment week 48)
Reported as:
Number · percentage of participants
Percentage of Participants With HCV-RNA Negativity at 24 Weeks of Treatment and at EOT
percentage of participantsPEG-IFN + Ribavirin
At 24 Weeks Treatment61.3
At End of Treatment66.7
PrimaryNumber of Participants Discontinuing Treatment

Prespecified adverse event discontinuance criteria included neutrophil count \<500 /mm3, platelet count \<50,000/mm3, and hemoglobin \<8.5 g/dL.

Time frame:
From time of first treatment to Week 48
Reported as:
Number · participants
Number of Participants Discontinuing Treatment
participantsPEG-IFN + Ribavirin
Due To Decrease in Neutrophil Count3
Due To Decrease in Neutrophil and Platelet Count1
Due To Apathy1
Due To Pleural Effusion1
Due To Pregnancy of Participant's Partner1
Due To No Visit1
Due To Withdrawal by Subject2
Total Number Discontinued10

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PEG-IFN + Ribavirin—7/75 (9.3%)75/75 (100%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventPEG-IFN + Ribavirin
MENINGOCELECongenital, familial and genetic disorders1/75
VERTIGOEar and labyrinth disorders1/75
CATARACTEye disorders1/75
COLITIS ISCHAEMICGastrointestinal disorders1/75
LABYRINTHITISInfections and infestations1/75
NEUTROPHIL COUNT DECREASEDInvestigations1/75
CEREBRAL VENTRICLE DILATATIONNervous system disorders1/75
PREMATURE BABYPregnancy, puerperium and perinatal conditions1/75
THREATENED LABOURPregnancy, puerperium and perinatal conditions1/75
DEPRESSIONPsychiatric disorders1/75
Most frequent other events
Showing 10 of 89
Most frequent other events
EventPEG-IFN + Ribavirin
PYREXIAGeneral disorders73/75
WHITE BLOOD CELL COUNT DECREASEDInvestigations73/75
LYMPHOCYTE COUNT DECREASEDInvestigations71/75
NEUTROPHIL COUNT DECREASEDInvestigations69/75
HEADACHENervous system disorders68/75
MALAISEGeneral disorders66/75
ALOPECIASkin and subcutaneous tissue disorders63/75
RED BLOOD CELL COUNT DECREASEDInvestigations59/75
HAEMATOCRIT DECREASEDInvestigations58/75
HAEMOGLOBIN DECREASEDInvestigations58/75

Baseline characteristics

Age, Continuous
Age, Continuous(years)PEG-IFN + Ribavirin
Mean55.1 ± 9.7
Age, Customized
Age, Customized(participants)PEG-IFN + Ribavirin
< 65 yrs64
≥ 65 yrs11
Sex: Female, Male
Sex: Female, Male(Participants)PEG-IFN + Ribavirin
Female70
Male5
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2012, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2008
First posted
May 30, 2008
Start
Jan 2008
Primary completionActual
Dec 2010
CompletionActual
Dec 2010
Results first posted
Jan 18, 2012
Last update
Apr 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00686777
Responsible party
Sponsor
First posted
May 30, 2008
Start date
Jan 2008
Primary completion
Dec 2010
Completion
Dec 2010
Results posted
Jan 18, 2012
Last update
Apr 7, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Peginterferon alfa-2b · Ribavirin

Start the discussion